Literature DB >> 11587642

Complex between Peptostreptococcus magnus protein L and a human antibody reveals structural convergence in the interaction modes of Fab binding proteins.

M Graille1, E A Stura, N G Housden, J A Beckingham, S P Bottomley, D Beale, M J Taussig, B J Sutton, M G Gore, J B Charbonnier.   

Abstract

BACKGROUND: Peptostreptococcus magnus protein L (PpL) is a multidomain, bacterial surface protein whose presence correlates with virulence. It consists of up to five homologous immunoglobulin binding domains that interact with the variable (VL) regions of kappa light chains found on two thirds of mammalian antibodies.
RESULTS: We refined the crystal structure of the complex between a human antibody Fab fragment (2A2) and a single PpL domain (61 residues) to 2.7 A. The asymmetric unit contains two Fab molecules sandwiching a single PpL domain, which contacts similar VL framework regions of two light chains via independent interfaces. The residues contacted on VL are remote from the hypervariable loops. One PpL-Vkappa interface agrees with previous biochemical data, while the second is novel. Site-directed mutagenesis and analytical-centrifugation studies suggest that the two PpL binding sites have markedly different affinities for VL. The PpL residues in both interactions are well conserved among different Peptostreptococcus magnus strains. The Fab contact positions identified in the complex explain the high specificity of PpL for antibodies with kappa rather than lambda chains.
CONCLUSIONS: The PpL-Fab complex shows the first interaction of a bacterial virulence factor with a Fab light chain outside the conventional combining site. Structural comparison with two other bacterial proteins interacting with the Fab heavy chain shows that PpL, structurally homologous to streptococcal SpG domains, shares with the latter a similar binding mode. These two bacterial surface proteins interact with their respective immunoglobulin regions through a similar beta zipper interaction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11587642     DOI: 10.1016/s0969-2126(01)00630-x

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  34 in total

1.  Specific in vivo deletion of B-cell subpopulations expressing human immunoglobulins by the B-cell superantigen protein L.

Authors:  Muriel Viau; Nancy S Longo; Peter E Lipsky; Lars Björck; Moncef Zouali
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

2.  Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia.

Authors:  Fabio Ghiotto; Franco Fais; Angelo Valetto; Emilia Albesiano; Shiori Hashimoto; Mariella Dono; Hideyuki Ikematsu; Steven L Allen; Jonathan Kolitz; Kanti R Rai; Marco Nardini; Anna Tramontano; Manlio Ferrarini; Nicholas Chiorazzi
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

Review 3.  B cell superantigens: a microbe's answer to innate-like B cells and natural antibodies.

Authors:  Carl S Goodyear; Gregg J Silverman
Journal:  Springer Semin Immunopathol       Date:  2005-03

4.  Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodies.

Authors:  Joshua M Donaldson; Cindy Zer; Kendra N Avery; Krzysztof P Bzymek; David A Horne; John C Williams
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-07       Impact factor: 11.205

5.  Non-canonical binding of an antibody resembling a naïve B cell receptor immunoglobulin to hepatitis B virus capsids.

Authors:  Norman R Watts; Giovanni Cardone; Joe G Vethanayagam; Naiqian Cheng; Catharina Hultgren; Stephen J Stahl; Alasdair C Steven; Matti Sällberg; Paul T Wingfield
Journal:  J Mol Biol       Date:  2008-04-09       Impact factor: 5.469

6.  Controlled conductivity at low pH in Protein L chromatography enables separation of bispecific and other antibody formats by their binding valency.

Authors:  Chen Chen; Tetsuya Wakabayashi; Masaru Muraoka; Feng Shu; Chia Wei Shan; Chong Chor Kun; Ching Tim Jang; Ishin Soehano; Yuichiro Shimizu; Tomoyuki Igawa; Jun-Ichi Nezu
Journal:  MAbs       Date:  2019-03-21       Impact factor: 5.857

7.  MET-activating Residues in the B-repeat of the Listeria monocytogenes Invasion Protein InlB.

Authors:  Willem M Bleymüller; Nina Lämmermann; Maria Ebbes; Daniel Maynard; Christina Geerds; Hartmut H Niemann
Journal:  J Biol Chem       Date:  2016-10-27       Impact factor: 5.157

8.  A structurally distinct human mycoplasma protein that generically blocks antigen-antibody union.

Authors:  Rajesh K Grover; Xueyong Zhu; Travis Nieusma; Teresa Jones; Isabel Boreo; Amanda S MacLeod; Adam Mark; Sherry Niessen; Helen J Kim; Leopold Kong; Nacyra Assad-Garcia; Keehwan Kwon; Marta Chesi; Vaughn V Smider; Daniel R Salomon; Diane F Jelinek; Robert A Kyle; Richard B Pyles; John I Glass; Andrew B Ward; Ian A Wilson; Richard A Lerner
Journal:  Science       Date:  2014-02-07       Impact factor: 47.728

9.  The B-cell superantigen Finegoldia magna protein L causes pulmonary inflammation by a mechanism dependent on MyD88 but not B cells or immunoglobulins.

Authors:  Amy L Anderson; Yi Zheng; Decheng Song; David Larosa; Nico Van Rooijen; Gerold Kierstein; Sonja Kierstein; Angela Haczku; Arnold I Levinson
Journal:  Inflamm Res       Date:  2012-01-17       Impact factor: 4.575

10.  Fold and function of the InlB B-repeat.

Authors:  Maria Ebbes; Willem M Bleymüller; Mihaela Cernescu; Rolf Nölker; Bernd Brutschy; Hartmut H Niemann
Journal:  J Biol Chem       Date:  2011-02-23       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.